Evozyne Collaborates to Develop Immune Modulation Biopharmaceuticals

Evozyne, LLC is a molecular engineering platform for building novel and application-specific proteins with advanced functionality. They use data-driven tech to accelerate evolution computationally. Through a combination of nature and machine learning, they intend to create extraordinary proteins. They use deep learning-based computational models and high-throughput gene synthesis to produce novel, dapative proteins. They want to solve worldly challenges by feeding the world, curing diseases, cleaning our environment, and creating sustainable materials.

Recently, they have established a collaboration to develop novel biopharmaceuticals for immune modulation. This collaboration with a company leading in rare disorders research will help to advance Evozyne as a primary enabler of synthetic biology. They hope the development of these synthetic proteins can impact people living with debilitating diseases. This partnership will have Evozyne responsible for protein design and research and development, while their partner will tackle the commercialization activities. They have yet to identify the partner.

Are you developing new products? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts